High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Blood. 2025 Jun 11:blood.2025028313. doi: 10.1182/blood.2025028313.…
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Blood Adv. 2025 Jun 5:bloodadvances.2024015274. doi: 10.1182/bloodadvances.2024015274.…
Setting up a CAR-T Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplant Cell Ther. 2025 May 23:S2666-6367(25)01196-0. doi:…
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Blood. 2025 May 22:blood.2025029234. doi: 10.1182/blood.2025029234.…
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group
Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568-4.…
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study
Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137.ABSTRACTBACKGROUND/OBJECTIVES:…
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis
Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557-7.…
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
Blood. 2025 Apr 3;145(14):1444-1445. doi: 10.1182/blood.2024028030.NO…
Celebrating 5 years of Women in Lymphoma: a road to equality, diversity, and inclusion in the field
Lancet Haematol. 2025 Apr;12(4):e246-e247. doi: 10.1016/S2352-3026(25)00070-5.NO…
Autologous Stem Cell Transplantation for Relapsed/Refractory Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study
Blood Adv. 2025 Mar 31:bloodadvances.2024015415. doi: 10.1182/bloodadvances.2024015415.…
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma
Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539-9.…
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
Blood. 2025 Feb 19:blood.2024025131. doi: 10.1182/blood.2024025131.…
